



HAL
open science

Broad-Range Papillomavirus Transcriptome as a Biomarker of Papillomavirus-Associated Cervical High-Grade Cytology

Philippe Pérot, Anne Biton, Jacques Marchetta, Anne-Gaelle Pourcelot, André Nazac, Henri Marret, Thomas Hebert, Delphine Chrétien, Marie-Christine Demazoin, Michael Falguières, et al.

► To cite this version:

Philippe Pérot, Anne Biton, Jacques Marchetta, Anne-Gaelle Pourcelot, André Nazac, et al.. Broad-Range Papillomavirus Transcriptome as a Biomarker of Papillomavirus-Associated Cervical High-Grade Cytology. *Journal of Molecular Diagnostics*, 2019, 21 (5), pp.768-781. 10.1016/j.jmoldx.2019.04.010 . pasteur-02613507

HAL Id: pasteur-02613507

<https://pasteur.hal.science/pasteur-02613507>

Submitted on 20 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **TITLE**

2 Broad range papillomavirus transcriptome as a biomarker of papillomavirus-associated cervical high-
3 grade cytology

4 **AUTHORS**

5 Philippe Pérot¹, Anne Biton², Jacques Marchetta³, Anne-Gaelle Pourcelot⁴, André Nazac⁴, Henri
6 Marret⁵, Thomas Hébert⁵, Delphine Chrétien¹, Marie-Christine Demazoin⁶, Michaël Falguières⁶,
7 Laurence Arowas⁶, Hélène Laude⁶, Isabelle Heard⁶ and Marc Eloit^{1,7*}

8 ¹ Pathogen Discovery Laboratory, Biology of Infection Unit, Institut Pasteur, Paris, France

9 ² Centre de bioinformatique, biostatistique et biologie intégrative (C3BI), Institut Pasteur, Paris, France

10 ³ Centre Hospitalier Universitaire, Angers, France

11 ⁴ Hôpital Le Kremlin-Bicêtre, France

12 ⁵ Centre Olympe de Gouges, CHU Bretonneau, Tours, France

13 ⁶ Centre National de Reference des Papillomavirus, Institut Pasteur, Paris, France

14 ⁷ National Veterinary School of Alfort, Paris-Est University, Maisons-Alfort, 94704 Cedex, France

15 * Corresponding author: Marc Eloit marc.eloit@pasteur.fr +33(0)144389216

16 **SHORT RUNNING HEAD:** HPV RNA-Seq

17 **FUNDING:** This work was funded by Institut Pasteur (grants InnovDiag and Pasteur Innov), Paris,
18 France.

19 **COMPETING INTERESTS:** PP, AB, IH and ME have submitted patent applications covering the findings
20 of this work.

21 This manuscript contains 33 pages (MS Word), 3 figures, 7 tables, 3 supplemental figures and 4
22 supplemental tables.

23

24 **ABSTRACT**

25 Human Papillomaviruses (HPV) are responsible for over 99% of cervical cancers. Molecular diagnostic
26 tests based on the detection of viral DNA or RNA have low Positive Predictive Values (PPV) for the
27 identification of cancer or precancerous lesions. Triage with the Papanicolaou test lacks sensitivity and
28 even when combined with molecular detection of high-risk HPV results in a significant number of
29 unnecessary colposcopies. We have developed a broad range detection test of HPV transcripts to take
30 a snapshot of the transcriptome of 16 high-risk or putative high-risk HPV in cervical lesions (HPV16, 18,
31 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82). The purpose of this novel molecular assay is
32 to detect and type HPV-positive samples and to determine a combination of HPV reads at certain
33 specific viral spliced junctions that can better correlate with high-grade cytology, reflecting the
34 presence of precancerous cells. In a proof-of-concept study conducted on 55 patients, starting from
35 cervical smears, we have shown that (i) HPV RNA-Seq can detect papillomaviruses with performances
36 comparable to a widely used HPV reference molecular diagnostic kit, and (ii) a combination of the
37 number of sequencing reads at specific early vs late HPV transcripts can be used as a marker of high-
38 grade cytology, with encouraging diagnostic performances as a triage test.

39

40

41

42

43

44

45

46

48 INTRODUCTION

49 Human papillomaviruses (HPV) infections are associated with the development of cervical carcinoma,
50 one of the most common cancers among women, and other cancers like anal cancer¹ and head and
51 neck cancer². HPV are the etiologic agents responsible for over 99% of all cervical cancers³. HPV are
52 small, non-enveloped DNA viruses commonly transmitted through sexual contact, which infect basal
53 cells and replicate in the nucleus of squamous epithelial cells. HPV include more than 200 genotypes
54 characterized by their oncogenic potential, with highly oncogenic HPV types (high-risk HPV) having a
55 unique ability to drive cell proliferation⁴.

56 The genomic organization of papillomaviruses is divided into functional early and late regions. The
57 model of HPV infection, which is mainly derived from knowledge on HPV16, is that following the
58 infection of basal cells in the cervical epithelium, the early HPV genes (*E6*, *E7*, *E1*, *E2*, *E4* and *E5*) are
59 expressed and the viral DNA replicates from the episomal form of the viral DNA. As the cells divide, in
60 the upper layers of the epithelium the viral genome is replicated further, and the late genes (*L1* and
61 *L2*) and *E4* are expressed. Viral shedding then further initiates new infections⁵.

62 HPV infection during the development of cervical cancer is associated with a shift from productive
63 infection (which in most of the cases will be cleared by the immune system), towards non-productive
64 persistent and transforming infection (in a minority of cases) characterized in particular by a high level
65 of *E6* and *E7* mRNAs and low expression of *E2* and late genes such as *L1*^{6,7}. High-risk HPV infection may
66 result in low-grade lesion, with highly productive infection and high rate of spontaneous regression. In
67 contrast, high-risk persistent HPV infection is responsible for high-grade lesion, the true precancerous
68 lesion.

69 Cervical cancer screening allows detection and treatment of precancerous lesions before the
70 development of cervical cancer. Screening is based on different algorithms, some allowing detection
71 of HPV, and others identifying abnormal cells. Despite the role of high-risk HPV in cervical cancer,

72 screening tests of cancer or precancerous lesions remain in many countries mainly based on the
73 Papanicolaou (Pap) cytology test and do not include molecular virology tests⁴. This is largely due to the
74 low Positive Predictive Value (PPV) of current molecular tests. Indeed, because most of the current
75 molecular diagnostic methods rely on the detection of HPV genome (DNA) and do not address the
76 patterns of viral expression (RNA), they remain weak predictors of the evolution from low-grade
77 squamous intraepithelial lesion (LSIL) to high-grade squamous intraepithelial lesion (HSIL) of the
78 cervix⁸. In addition, DNA identification of high-risk HPV is not fully predictive of cancer since only
79 persistence for years of high-risk HPV is associated with an increased risk of cancer development⁴.
80 Thus, the use of HPV DNA tests, as a screening assay, is currently increasing worldwide and shows high
81 sensitivity⁹ but low PPV for HSIL detection¹⁰.

82 HPV RNA tests and in particular the detection of E6 and E7 mRNAs of high-risk HPV have been
83 proposed as better molecular markers of cancer development, but *E6* and *E7* are also expressed
84 during HPV transient infection so it remains difficult to define a threshold of expression associated
85 with the persistence and evolution to high-grade lesions and cancer. There is no consensus that HPV
86 RNA tests have a better diagnostic accuracy compared to HPV DNA tests and cytology for the
87 detection of cervical precancerous lesions¹¹⁻¹³. There is therefore a need for a novel generation of
88 molecular diagnostic tests that can not only detect HPV infection, but also have the ability to
89 accurately predict precancerous stages to offer a better and cost saving medical benefit¹⁴⁻¹⁶.

90 We took advantage of Next-Generation Sequencing (NGS) technologies that now make it possible to
91 study populations of transcripts as a whole, instead of focusing only on one or two specific messenger
92 RNA as done with former techniques such as quantitative RT-PCR used in HPV RNA tests. To do so, we
93 have developed a multiplexed amplification system targeting the virus splice junctions coupled with
94 NGS analysis, tentatively named HPV RNA-Seq (based on the AmpliSeq technology), that allows to
95 describe fine equilibrium among transcript species of 13 high-risk HPV (HPV16, 18, 31, 33, 35, 39, 45,
96 51, 52, 56, 58, 59, 66) plus 3 putative high-risk HPV (HPV68, 73, 82), in a single reaction. This
97 molecular approach makes, in particular, possible to take a snapshot of the early vs late populations of

98 HPV transcripts and to define a model based on a combination of reads that reflects the biology of the
99 virus, which can then be correlated with the evolution of cervical lesions. The ultimate goal is to
100 replace the current combination of cytology (Pap smear) and HPV molecular screening by a single
101 molecular test for both the detection of high-risk or putative high-risk HPV and the triage of women at
102 risk of transforming infection, before colposcopy.

103 In this proof-of-concept study conducted on 55 patients (27 HSIL, 28 LSIL), starting from cervical
104 smears conserved at room temperature, we have shown that (i) HPV RNA-Seq can detect
105 papillomaviruses with performances comparable to a HPV DNA-based reference diagnostic kit¹⁷, and
106 (ii) a combination of the number of sequencing reads at specific early vs late HPV RNA spliced
107 junctions can be used as a marker of high-grade cytology, with encouraging diagnostic performances
108 as a triage test.

109

110 **MATERIALS AND METHODS**

111 **Ethics approval and consent to participate:** This work was approved by the Comité de Protection des
112 Personnes Ile de France 1 (CPP IDF1) and by the Agence Nationale de Sécurité des Médicaments et
113 des Produits de Santé (ANSM). The data processing was authorized by the Commission Nationale de
114 l'Informatique et des Libertés (CNIL). Patients provided written informed consent to participate in the
115 study.

116 **Evaluation of transport medium for RNA conservation**

117 HPV16-positive cervical squamous cell carcinoma SiHa cells were cultivated and inoculated at a final
118 concentration of 7×10^4 cells/mL in four transport medium: PreservCyt Solution (Hologic, USA),
119 NovaPrep HQ+ Solution (Novaprep, France), RNA Protect Cell Reagent (Qiagen, Germany) and
120 NucliSens Lysis Buffer (BioMérieux, France). The mixtures were aliquoted in 1mL tubes and kept at
121 room temperature for 2 hours (D0), 48 hours (D2), 168 hours (D7), 336 hours (D14) and 504 hours
122 (D21). In parallel, 7×10^4 cells pellets without transport medium were kept frozen -80°C for 2 hours, 48

123 hours, 168 hours, 336 hours and 504 hours as a control. At D0, D2, D7, D14 and D21, room
124 temperature aliquots were centrifuged, the medium removed, and the pellets were frozen -80°C for a
125 short time (<1h) before proceeding with RNA extraction. In the particular case of the NucliSens Lysis
126 Buffer since the cells were lysed, the entire 1mL aliquot was frozen -80°C for a short time without
127 prior centrifugation. For each sample, RNA was extracted using the PicoPure RNA Isolation kit (Thermo
128 Fisher Scientific, USA), together with the corresponding (time match) frozen control, so that all
129 samples have undergone one freezing cycle. RT-qPCR was performed to quantify the expression of the
130 two human genes *G6PD* (forward primer: TGCAGATGCTGTGTCTGG; reverse primer:
131 CGTACTGGCCCAGGACC) and *GAPDH* (forward primer: GAAGGTGAAGGTCGGAGTC; reverse primer:
132 GAAGATGGTGATGGGATTTTC) and the expression of the two viral genes HPV16 *E6* (forward primer:
133 ATGCACCAAAGAGAACTGC; reverse primer: TTACAGCTGGGTTTCTCTAC) and *E7* (forward primer:
134 GTAACCTTTTGTGCAAGTGTGACT; reverse primer: GATTATGGTTTCTGAGAACAGATGG) (**Supplemental**
135 **Figure 1**). RNA integrity was assessed on a Bioanalyzer instrument (Agilent, USA) (**Supplemental**
136 **2**).

137 HPV selection and splice sites analysis

138 HPV reference clones made available by the International Human Papillomavirus Reference Center
139 (Karolinska University, Stockholm, Sweden) served as reference genomes, except for HPV68 which was
140 retrieved from Chen et al.¹⁸. Accession numbers used in this study were: K02718 (HPV16), X05015
141 (HPV18), J04353 (HPV31), M12732 (HPV33), X74477 (HPV35), M62849 (HPV39), X74479 (HPV45),
142 M62877 (HPV51), X74481 (HPV52), X74483 (HPV56), D90400 (HPV58), X77858 (HPV59), U31794
143 (HPV66), KC470267 (HPV68), X94165 (HPV73) and AB027021 (HPV82). Multiple alignment of HPV
144 genomes was done with ClustalW v2.1 using Geneious¹⁹ v10. Previously known splice donor (SD) and
145 splice acceptor (SA) sites for HPV16²⁰ and HPV18²¹ were reported on the alignment, and predictions of
146 unknown SD and SA sites were done manually for the other genotypes by sequence analogy (**Figure 1A**
147 **and 1B**).

148 HPV RNA-Seq AmpliSeq custom panel

149 A custom AmpliSeq panel was designed to be used on both PGM and Ion Proton instruments (Thermo
150 Fisher Scientific). Five categories of target sequences were defined as follow:

151 HPV spliced junctions (sp): a set of target sequences, which are specific HPV splice events, involving a
152 pair of splice donor (SD) and splice acceptor (SA) sites. The nomenclature includes a “sp” tag. For
153 example, “31_sp_1296_3295_J43-46” stands for HPV31 (31), splice junction (sp), SD at position 1296
154 on HPV31 genome, SA at position 3295 on HPV31 genome, and junction (J) at position 43-46 on
155 amplicon. The junction coordinates are given in a 4-bases interval, where the first 2 bases correspond
156 to the donor part (or left part) and the last 2 bases to the acceptor part (or right part) of the sequence.

157 HPV unspliced junctions (unsp): a set of target sequences which are specific HPV genomic regions
158 spanning either SD or SA sites, in the absence of any splice event. The nomenclature includes an
159 “unsp” tag. For example, “31_unsp_1296_1297_J43-46” stands for HPV31 (31), unspliced (unsp), last
160 base of the left part of the amplicon at position 1296 on HPV31 genome, first base of the right part of
161 the amplicon at position 1297 on HPV31 genome, junction (J) at position 43-46 on amplicon. In this
162 context, the term ‘junction’ refers to the exon-intron interface (ie the position where a donor or
163 acceptor site would be found in case of a splice event), and the associated junction coordinates are
164 used to characterize unspliced sequences bioinformatically as described in section “Sequencing data
165 processing”.

166 HPV genome away from spliced junctions (gen): a set of target sequences which are specific HPV
167 genomic regions, away from any SD or SA sites. The nomenclature includes a “gen” tag. For example,
168 “45_gen_1664_1794_NoJ” stands for HPV45 (45), HPV genomic region (gen), amplicon coordinates
169 from position 1664 to position 1794 on HPV45 genome.

170 HPV-human fusion sequences (fus): a set of hypothesis-driven viral-cellular fusion transcripts, based
171 on previous descriptions²²⁻²⁶. For each HPV, 18 fusion sequence candidates involving SA2 or putative
172 breakpoint 1 or 2 (put. bkpt, see **Figure 1B**) for the viral part, and specific exons from *MYC* or *PVT1*
173 oncogenes for the cellular part, were added to the design. For example,
174 “18_fus_929_MYC_001_exon3_J37-40” stands for HPV18 (18), candidate fusion transcript (fus),

175 break/fusion at position 929 on HPV18 genome, fused with MYC mRNA isoform 001 exon 3, junction
176 (J) at position 37-40 on amplicon.

177 Human sequences (hg): a set of 30 human sequences used as internal controls retrieved from
178 publically available AmpliSeq projects and representing housekeeping genes (*ACTB*, *B2M*, *GAPDH*,
179 *GUSB*, *RPLP0*), epithelial markers (*KRT10*, *KRT14*, *KRT17*), oncogenes, tumor suppressor genes, and
180 direct or indirect downstream effectors of HPV oncoproteins (*AKT1*, *BCL2*, *BRAF*, *CDH1*, *CDKN2A*,
181 *CDKN2B*, *ERBB2*, *FOS*, *HRAS*, *KRAS*, *MET*, *MKI67*, *MYC*, *NOTCH1*, *PCNA*, *PTEN*, *RB1*, *STAT1*, *TERT*,
182 *TOP2A*, *TP53*, *WNT1*). The nomenclature for these sequences includes an “hg” tag. For example,
183 “hg_TOP2A_E21E22” stands for human topoisomerase 2A mRNA exon 21-22.

184 In total, 750 target sequences were included into the panel (**Table 1**) and can be amplified with a pool
185 of 525 unique primers (**Supplemental Table S1**). The custom panel is registered under number
186 WG_WG00141 (Ion AmpliSeq Designer). The average amplicon size of the panel (primers included) is
187 141bp (range: 81-204bp). A detailed table including amplicons names and characteristics along with
188 their corresponding primers and amplicon sequences is given in the **Supplemental Table S1**.

189 **Study participants**

190 Study participants were women aged from 25 to 65 years old referred for colposcopy consultation in
191 French hospitals. The patients were referred for colposcopy in the context of a LSIL or a HSIL result at
192 their cytology test performed in accordance with French recommendations regarding the cervical
193 cancer screening program. Patients provided written informed consent according to French
194 legislation.

195 **Specimen collection**

196 Genital samples were collected just before performing colposcopy using a cervical sampling device,
197 immersed and rinsed in a vial filled with 20mL of PreservCyt Solution (Hologic), and sent at room
198 temperature to the HPV National Reference Center (CNR) at Institut Pasteur, Paris, France. From July
199 2014 to April 2015, 84 patients were enrolled in the study, coming from 3 different French centers:

200 CHU Angers (n=66); CHU Kremlin-Bicêtre (n=10); CHU Tours (n=6). Samples were removed from the
201 study because of technical reasons (sample leakage, n=1), legal issues (n=7) or because they were
202 used for initial technical tests (RNA conservation, RNA extraction and amplification, n=4). The
203 remaining 72 samples (HSIL=37; LSIL=35) were processed (**Supplemental Table S2**).

204 **Data collection**

205 The following bio-clinical data were collected: date and results of the cytology test, age at the time of
206 the cytology test, date and results of all available histological results posterior to colposcopy. As
207 colposcopy was performed in the context of routine healthcare, biopsies were not performed in case
208 of normal colposcopy.

209 **HPV DNA detection using the PapilloCheck Test Kit (HPV DNA)**

210 Upon reception at CNR, 16 mL of cytological sample were transferred into a 50 mL Falcon tube and
211 centrifuged at 4,500 g for 10 minutes. The supernatant was removed and the pellet washed with 1 mL
212 of PBS. Sample was then centrifuged again at 5,000 g for 10 minutes and the supernatant removed.
213 The pellet was frozen at -80°C before DNA extraction. Following DNA extraction (Macherey Nagel,
214 Germany), HPV detection was done using the PapilloCheck Test Kit (Greiner Bio-One GmbH, Germany)
215 according to manufacturer instructions (**Supplemental Table S2**).

216 **RNA extraction and characterization**

217 In parallel to the HPV DNA procedure, 3 x 1 mL aliquots of cytological specimen were centrifuged at
218 14,000 rpm for 7 minutes, the supernatant was removed and the pellet was washed with 1 mL of PBS.
219 Sample was then centrifuged again at 14,000 rpm for 7 minutes and the supernatant removed. The
220 pellet was frozen at -80°C before RNA extraction. RNA extractions were done using the PicoPure RNA
221 Isolation kit (Thermo Fisher Scientific), including on-column DNase treatment, with a final elution
222 volume of 30 µL. Total RNA was quantified on a Nanodrop (Life Technologies, USA) and RNA integrity
223 was evaluated on a Bioanalyzer RNA 6000 pico chip (Agilent) using the RIN (RNA Integrity Number), a
224 quality score ranging from 1 (strongly degraded RNA) to 10 (intact RNA). For each sample, RT-qPCR

225 targeting mRNA from housekeeping genes *ACTB* (forward primer: CATCGAGCACGGCATCGTCA; reverse
226 primer: TAGCACAGCCTGGATAGCAAC; amplicon size = 210bp), and *GAPDH* (forward primer:
227 GAAGGTGAAGGTCGGAGTC; reverse primer: GAAGATGGTGATGGGATTTTC; amplicon size = 226bp) were
228 done in a SYBR Green format with 45 cycles of amplification. RT-negative (RT-) PCR were run to
229 evaluate the presence of residual DNA after RNA extraction (**Supplemental Table S2**).

230 **Amplification and sequencing**

231 Starting from RNA, cDNA were generated using the SuperScript III (n=17 samples) or SuperScript IV
232 (n=55 samples) first strand synthesis system (Thermo Fisher Scientific) with random hexamers and a
233 final RNase H treatment. Libraries were prepared using the Ion AmpliSeq Library Kit 2.0 and AmpliSeq
234 custom panel WG_WG00141, with 21 cycles of amplification before adapter's ligation. Each sample
235 was barcoded individually. Only positive libraries were sequenced (**Supplemental Table S2**). In total, 55
236 clinical samples plus 1 cellular model (SiHa) were sequenced on 4 Ion Proton runs. Raw data (.fastq
237 files) are available on the NCBI SRA database under BioProject accession number PRJNA525642.

238 **Sequencing data processing**

239 Reads were aligned to the reference sequences of the amplicons using STAR²⁷ v2.5.3a in local
240 alignment mode (parameter --alignEndsType EndToEnd), by only reporting uniquely mapped reads (--
241 outFilterMultimapNmax 1) and turning off splicing alignment (--alignIntronMax 1). The expression of
242 each amplicon was evaluated by the number of sequencing reads uniquely mapping to their
243 respective sequence (read counts). For reference sequences containing a splice junction, only reads
244 mapping at the junction site and encompassing at least 10 bases before and 10 bases after the
245 junction were kept. Read counts for each sequence and each sample are provided in the **Supplemental**
246 **Table S3**.

247 **HSIL prediction model**

248 Selection of amplicons

249 Read counts were normalized by the size of the library (each read count was divided by a ratio of the
250 library size for a given sample to that of the average library size across samples) and the 215
251 amplicons capturing splice junctions (sp) of the 16 high-risk or putative high-risk HPV were selected.
252 These amplicons have been annotated with generic names with respect to the type of transcripts they
253 capture, which are shared across HPV species (e.g. "SD1-SA1", see **Figure 1B** and **Supplemental Table**
254 **S1**). Amplicons capturing splice junctions conserved across the 16 HPV species were summed up,
255 leading to the definition of 18 variables used as predictors in the model. 33 out of the 55 clinical
256 samples have been selected as presenting enough coverage of these specific amplicons (20 mono-
257 infected and 13 multi-infected samples). The remaining 22 samples of the dataset were not used in
258 the logistic regression analysis because they had missing or too low expression signal at spliced
259 junctions for the prediction, reflecting for example HPV-negative samples.

260 Logistic regression model

261 Calling high-grade cytology Y as taking the value 1 for high-grade (HSIL) and 0 for low-grade (LSIL), and
262 a set of amplicons x , a logistic regression model was used to predict the probability that a given
263 observation belongs to the "1" class versus the probability that it belongs to the "0" class. Logistic
264 regression models the log odds of the event (here the grade of the cytology) as a function of the
265 predictor variables (here the amplicon expression estimated by its read count). Formally, the logistic
266 regression model assumes that the log odds is a linear function of the predictors:

$$267 \text{logit}(\rho) = \ln\left(\frac{\rho}{1-\rho}\right) = b_0 + b^t \mathbf{x}$$

268 where $\rho = P(\mathbf{y} = 1 | \mathbf{x})$ indicates the probability of the event (being of high-grade), β_i are the
269 regression coefficients, and x_i the explanatory variables, in our case the log2 number of reads mapping
270 to the amplicons.

$$271 \text{Solving for } \pi, \text{ this gives: } \rho = \frac{1}{1 + e^{-(b_0 + b\mathbf{x})}}$$

272 Implementation of the logistic regression model

273 To limit overfitting, we used L2-norm (ridge) regularization, which allows shrinking the magnitudes of
274 the regression coefficients such that they will better fit future data. We estimated the logistic model
275 using the R (<http://www.r-project.org/> ; last accessed on January 29, 2019) package *glmnet*²⁸. Leave-
276 one-out (LOO) cross-validation was used to pick the regularization parameter λ , the one that gives
277 minimum mean cross-validated misclassification error was used. Using λ as the regularization
278 parameter, the model output consisted in an estimate of a coefficient value β for each variable in the
279 logistic regression model. This model was then used to predict the grade of the multi-infected
280 observations, by treating each HPV species separately.

281 Training set and test set

282 The model was built upon the clinical outcome LSIL or HSIL obtained from the cytological analysis, and
283 estimated on a training set consisting of 20 mono-infected samples (5 LSIL and 15 HSIL) in order to
284 avoid a confusion bias. It is indeed anticipated that, in the case of multi-infected samples, several HPV
285 could contribute differently to the progression of the lesion, or to a mix of several grades within the
286 same sample, because they are engaged in different stages of their cycle. The performance of the
287 model was then evaluated on a test set consisting of 13 multi-infected samples. In this case, the set of
288 amplicons of each HPV species was used separately to classify the multi-infected samples, to get one
289 prediction per HPV, as done for the mono-infected samples. For example if a sample had expression of
290 amplicons from both HPV16 and HPV32, two predictions were given: one using only sequencing reads
291 mapping to HPV16, and one using only sequencing reads mapping to HPV32. Like this it became
292 possible to interpret the results finely from a virological point of view, as we could discriminate which
293 HPV was responsible of the lesion.

294

295 **RESULTS**

296

297 Evaluation of transport medium for RNA conservation

298 The stability of total RNA from cervical cells at room temperature was evaluated in four solutions:
299 PreservCyt (Hologic), the most widely used solution for gynecological specimen collection; NovaPrep
300 HQ+ Solution (Novaprep), a competitor product used for cells and DNA recovery but never evaluated
301 for RNA conservation; RNA Protect Cell Reagent (Qiagen), a popular solution for RNA stability; and
302 NucliSens Lysis Buffer (BioMérieux), a lysis buffer part of the NucliSens automated acid nucleic
303 procedure which has been described as a RNA stabilizer (unpublished data). The amount of spiked
304 HPV16-positive cervical squamous cell carcinoma cells (SiHa) was calibrated to be representative of a
305 cervical smear. After 48h at room temperature, RT-qPCR measurement of cellular and viral transcripts
306 showed no or little RNA loss in PreservCyt, only limited RNA degradation (<1 log) in RNA Protect and
307 NucliSens Lysis Buffer, and a marked RNA loss in NovaPrep HQ+ Solution (>2 log) (**Supplemental Figure**
308 **1**). After 7 days and up to 21 days, only the PreservCyt solution provided RNA quality with a limited
309 RNA degradation pattern as indicated by the detection of 18S and 28S rRNA (**Supplemental Figure 2**).
310 We therefore decided to use the PreservCyt solution to collect the gynecological specimen of the
311 study.

312

313 HPV RNA-Seq AmpliSeq custom panel

314 Transcriptomic maps known for HPV16²⁰ and HPV18²¹ were used to predict unknown but likely splice
315 donor and splice acceptor sites for HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82 (**Figures**
316 **1A and 1B**). The resulting reconstructed transcripts, as well as HPV genomic sequences, were used as a
317 template for the design of an Ion AmpliSeq panel targeting 16 high-risk or putative high-risk HPV and
318 named HPV RNA-Seq. Putative breakpoints in HPV genomes, and 30 human cellular genes used as
319 internal controls, were also added to the design. In total, 750 sequences are targeted by a single mix
320 made of 525 unique primers (**Table 1 and Supplemental Table S1**).

321

322 Samples, RNA & sequencing

323 72 gynecological samples (HSIL=37; LSIL=35) coming from 3 different French centers (Angers, Kremlin-
324 Bicêtre and Tours) and collected in PreservCyt solution were processed with RNA extraction using a
325 method designed to recover total RNA from as little as a single cell (PicoPure RNA Isolation kit, Thermo
326 Fisher Scientific) (**Supplemental Table S2**). In most of the cases total RNA was measurable using a
327 Nanodrop (70/72 positive, average on positive RNA eluates = 18 ng/ μ L) and was detectable on a
328 Bioanalyzer pico RNA chip with a pattern indicating RNA degradation (63/72 positive, average RNA
329 Integrity Number on positive = 2.2). RT-qPCR performed for all samples on ACTB mRNA (amplicon size
330 = 210bp) and GAPDH mRNA (amplicon size = 226bp) indicated that RNA quality was compatible with
331 amplification of 200-250bp size fragments (ACTB mRNA average Ct=27.8; GAPDH mRNA average
332 Ct=30.1). Samples that failed passing this initial RT-PCR quality control were not sequenced. qPCR
333 performed after omitting the reverse transcription step (RT-) were also run and showed in general no
334 or little traces of residual genomic DNA (ACTB DNA average Ct=38.4 ; GAPDH DNA average Ct=35.6).
335 Note, the presence of residual cellular DNA or HPV DNA in RNA preparation is not a major concern
336 since the AmpliSeq assay can differentiate between HPV transcripts and genomic sequences. AmpliSeq
337 libraries were initiated from total RNA and were positive after 21 cycles of amplification for 55
338 samples (i.e. detectable on a Bioanalyzer HS DNA chip). Attempts to add one or two amplification
339 cycles did not bring any significant improvement to the results (data not shown).

340

341 In total, 55 patients (HSIL=27; LSIL=28), plus SiHa HPV16-positive cells as a control, were sequenced on
342 Ion Proton. The sequencing reads were aligned to the target sequences and read counts were
343 generated (**Supplemental Table S3**). An average of 2.4 million usable reads per sample was reached
344 (min=0.02M; max=8.36M), among which an average of 2.1 million reads mapped to the human
345 sequences (hg) used as internal controls (min=0.01M; max=8.06M) (**Supplemental Table S3**). The
346 detection of highly expressed human sequences in all samples, even though inter-sample variations
347 were observed, contributed to validate the sequencing procedure, which is important especially for
348 the interpretation of HPV-negative samples. Rare non-zero values were also observed for some of the
349 numerous HPV-human fusion sequences (fus) that were hypothesized (**Supplemental Table S3**) but

350 were all false positives, identified as such because only half of the reference sequences were covered
351 by reads.

352

353 **HPV RNA-Seq used for HPV detection and genotyping**

354 The first application of HPV RNA-Seq is to detect the presence in a given sample of any of the 16 high-
355 risk or putative high-risk HPV targeted by the panel. The number of reads mapping to HPV-specific
356 amplicons (i.e. the sum of categories “sp”, “unsp” and “gen”) was used to detect the presence of a
357 given HPV genotype. To help determining a threshold for detection, we took as a reference a HPV DNA
358 test validated for clinical use (PapilloCheck, Greiner Bio-One GmbH). The best sensitivity and specificity
359 values between the two tests were obtained for threshold of 100-200 reads (**Figure 2**). For example, a
360 threshold value of 150 reads resulted in a Sensitivity ($Se_{(HPV-DNA)}$) of 97.3%, a Specificity ($Sp_{(HPV-DNA)}$) of
361 83.3%, leading to a Positive Predictive Value ($PPV_{(HPV-DNA)}$) of 92.3% and a Negative Predictive Value
362 ($NPV_{(HPV-DNA)}$) of 93.8% for detecting high-risk HPV in this population composed of around 50% of HSIL
363 and 50% of LSIL (**Table 2**, raw data in the **Supplemental Table S2** and **Supplemental Table S3**). A more
364 detailed view of the genotypes identified by both techniques is given in **Figure 3**. The number of
365 mono-infected, multi-infected, or HPV-negative samples identified by the two tests is summarized in
366 **Table 3**. Note that, because the HPV DNA test can detect the 16 high-risk or putative high-risk HPV
367 captured by HPV RNA-Seq (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 73, and 82) plus 8
368 additional low-risk HPV (HPV6, 11, 40, 42, 43, 44/45, 53 and 70), the comparison was based only on
369 the 16 HPV common to both tests.

370

371 Using a threshold value of 150 reads, HPV RNA-Seq detected two more positive patients than the HPV
372 DNA test (n=39 vs n=37, **Table 2**). HPV RNA-Seq identified the presence of more than one HPV for
373 three more patients than the HPV DNA test (n=13 vs n=10 multi-infected samples, **Table 3**). Globally,
374 HPV16 was found at a slightly weaker occurrence by HPV RNA-Seq (n=18 vs n=19) in favor of other
375 genotypes such as HPV31, 33, 45, 52, 56, 58 or 66 which were less commonly found by the HPV DNA
376 test (HPV31 n=5 vs n=4; HPV33 n=3 vs n=1; HPV45 n=3 vs n=2; HPV52 n=5 vs n=3; HPV56 n=4 vs n=2;

377 HPV58 n=5 vs n=4; HPV66 n=2 vs n=1, **Figure 3**). Apart from HPV16, only HPV51 was less frequently
378 found by HPV RNA-Seq than by HPV DNA (n=2 vs n=3). The cellular model (SiHa) gave only HPV16
379 signal in both tests, as expected (**Supplemental Table S3**).

380

381 **HPV RNA-Seq used as a marker of high-grade cytology**

382 We conducted an exploratory analysis on 20 of the mono-infected samples in which we showed that
383 HPV RNA spliced junctions could be used to predict high-grade cytology. We focused the analysis on
384 amplicons capturing splice junctions (category “sp”) to be sure to detect HPV transcripts. However,
385 the number of mono-infected samples (n=20) used as training set was small, in particular the number
386 of samples of LSIL (n=5). In this configuration, we were not able to perform a fully accurate variable
387 selection, i.e. to select the strict minimum number of amplicons that were necessary for HSIL versus
388 LSIL prediction and set the others to zero coefficient. In addition, we were not able to avoid over-
389 fitting, as using only 5 LSIL and 15 HSIL samples did not allow capturing the diversity of the whole
390 population. LOO cross-validation was used to pick the lambda giving the minimum cross-validated
391 error using ridge regularization. Lambda = 0.08 gave a mean cross-validated error of 15%. We also
392 computed a 20% prediction error using nested cross-validation. This error rate can be seen as an
393 indicator of how the model could fit future datasets. We used the corresponding parameter to fit a
394 regularized logistic regression model, assigning a coefficient to each amplicon (**Table 4**) and a
395 probability of being of high-grade to each sample (**Table 5**). The grade of the 20 mono-infected
396 samples was classified correctly, except for one observation (**Table 5**). It is interesting to note that this
397 unique misclassified sample (IonXpress_019_2613), which was classified LSIL by the cytological
398 analysis, was further found as containing a mixture of LSIL and HSIL lesions after histological
399 examination performed more than one year after the sampling done for HPV RNA-Seq/cytology.

400

401 The estimated model was then used to classify the 13 multi-infected samples, with each HPV species
402 present within one sample being classified individually for its implication in HSIL development. If at
403 least one HPV species gave a HSIL prediction, the sample was considered to be HSIL. We calculated

404 performances for HSIL prediction for all samples, considering as not being of high-grade both the six
405 samples without sufficient coverage of the splice junctions and the 16 HPV-negative samples not
406 exceeding the threshold of HPV detection. The calculated performances for HSIL prediction in
407 comparison to cytology for the 55 patients (mono-infected, multi-infected and HPV-negative) were
408 $Se_{(cyto)}=66.7\%$, $Sp_{(cyto)}=85.7\%$, $PPV_{(cyto)}=81.8\%$ and $NPV_{(cyto)}=72.7\%$ (**Table 6A**). The performances were
409 also calculated for the subset of 39 samples having at least one HPV identified by HPV RNA-Seq, giving
410 in this case $Se_{(cyto/HR+)}=94.7\%$, $Sp_{(cyto/HR+)}=80.0\%$, $PPV_{(cyto/HR+)}=81.8\%$ and $NPV_{(cyto/HR+)}=94.1\%$ (**Table 6B**).
411 Note that the ratio HSIL to LSIL remained similar between these two populations (around 1:1), making
412 the comparison of the PPV and the NPV possible. Finally a summary of the results for HPV detection
413 and genotyping (HPV RNA-Seq vs HPV DNA) and high-grade cytology prediction (HPV RNA-Seq vs
414 cytology), including posterior histological data of cervix biopsies when available, is presented in **Table**
415 **7**.

416

417 **HPV RNA-Seq used as a triage test**

418 The performances of HPV RNA-Seq as a triage test were evaluated using histology as gold standard.
419 Results from histological examination were, however, not available for all patients. The time interval
420 separating HPV RNA-Seq/cytology tests from histological analysis, varying between 0 and 780 days,
421 was another limitation in this study. To try to overcome these drawbacks, we compared the
422 performances of HPV RNA-Seq vs histology to the performances of cytology vs histology, considering
423 either all available samples (**Supplemental Table S4 A**), or only samples for which histology was done
424 less than 3 months after HPV RNA-Seq/cytology (**Supplemental Table S4 B**), or only samples for which
425 histology was done less than 6 months after HPV RNA-Seq/cytology (**Supplemental Table S4 C**). In
426 addition and for each category, we made the distinction between the performances obtained when
427 HPV RNA-Seq HPV-positive and HPV-negative patients were grouped together (**Supplemental Table S4**
428 **1&1'**), or when only HPV-positive patients were considered (**Supplemental Table S4 2&2'**). Calculation
429 of the PPV as a function of HSIL prevalence in the population was also done (**Supplemental Figure 3**
430 and **Supplemental Table S4**). All these results are given as Supplemental Data.

431

432 **DISCUSSION**

433 We have developed a highly-multiplexed RT-PCR assay coupled with Next-Generation Sequencing
434 (HPV RNA-Seq) combining HPV detection and genotyping together with predicting high-grade
435 cytology, starting from cervical specimens conserved at room temperature. A pilot study was
436 conducted on 55 patients.

437

438 The performances of HPV RNA-Seq used as a HPV detection and genotyping assay were evaluated in
439 comparison to the HPV DNA PapilloCheck kit (HPV DNA), which is officially approved for clinical use. A
440 good concordance of the results was observed between the two assays (Area Under Curve > 0.95,
441 **Figure 2**). A positive threshold of 150 reads resulted in high sensitivity and negative predictive value of
442 HPV RNA-Seq ($Se_{(HPV-DNA)}=97.3\%$, $NPV_{(HPV-DNA)}=93.8\%$, **Table 2**), along with a relatively high but lower
443 specificity and positive predictive value ($Sp_{(HPV-DNA)}=83.3\%$, $PPV_{(HPV-DNA)}=92.3\%$, **Table 2**) linked to the
444 identification of additional genotypes by HPV RNA-Seq not detected by HPV DNA. Because cervical
445 samples were split before independent extractions of RNA (HPV RNA-Seq) and DNA (HPV DNA), the
446 few differences observed between the two tests can reflect a non-homogeneous distribution of
447 infected cells. It is also important to note that PapilloCheck, like other HPV DNA tests, is not 100%
448 accurate^{29,30}, so it remained difficult to identify potential false positive results of HPV RNA-Seq versus
449 better sensibility. For example, three patients were classified as HPV-negative by Papillocheck but not
450 by HPV RNA-Seq. The number of RNA-Seq reads associated to HPV species in these three potential
451 false HPV-positive patients was close to the limit of detection for some of them (≤ 400 reads) but not
452 for all (e.g. 39527 reads mapped to HPV58 for sample 2065) (**Supplemental Table S3**). The calculated
453 sensitivity and specificity may therefore not reflect optimally the added value of HPV RNA-Seq. These
454 limitations are common for any novel diagnostic test when compared to older references.

455

456 Effective cervical cancer screening requires high Se and NPV for high-risk HPV detection, as women
457 with a negative HPV test are usually tested again only after several years. The positive threshold for

458 HPV genotyping was set at 150 reads in this study because it optimized both Se and Sp values, but
459 lowering this threshold in order to maximize the sensitivity remains possible. Such adjustments will be
460 possible following the study of larger cohorts.

461

462 As a second application of HPV RNA-Seq, as a triage test, a logistic regression model for the prediction
463 of high-grade cytology was built based on a combination of the number of reads captured at specific
464 HPV RNA spliced junctions, using the grade found by cytology as a reference. This evaluation was
465 conducted in a population of women with LSIL or HSIL cytology results. Where at least one HPV was
466 given a high-grade signature, the patient's prediction was set as "HSIL". Conversely, "Not HSIL" was
467 used when either no HPV was detected in the sample (threshold of 150 reads) or when none of the
468 genotypes detected by HPV RNA-Seq were given high-grade prediction (absence of detectable
469 transcripts). We preferred to use the terminology "Not HSIL" rather than "LSIL" because the protocol
470 did not allow the comparison of the HPV-DNA positive samples evaluated as LSIL with the ones
471 evaluated as normal in cytology. Also, because there is a possibility that cervical lesions could in some
472 rare cases originate from causes other than HPV infections, the use of "Not HSIL" instead of "LSIL" in
473 the case of HPV-negative samples seemed more appropriate.

474

475 As far as the comparison with cytology could be used as a benchmark, when the 55 patients were
476 considered (including mono-infected, multi-infected and HPV-negative), the number of HSIL predicted
477 by HPV RNA-Seq (n=22) was lower than the number of HSIL identified by cytology (n=27), resulting in
478 $Se_{(cyto)}=66.7\%$, $Sp_{(cyto)}=85.7\%$, $PPV_{(cyto)}=81.8\%$ and $NPV_{(cyto)}=72.7\%$ (**Table 6A**). Interestingly, when only
479 HPV RNA-Seq HPV-positive samples were considered, the **PPV**_(cyto/HR+) for the detection of high grade
480 lesions remained unchanged but the **Se**_(cyto/HR+) and the **NPV**_(cyto/HR+) increased to 94.7% (+28.0) and
481 94.1% (+21.4) respectively, with the number of HSIL predicted by HPV RNA-Seq (n=22) becoming
482 superior to the number of HSIL identified by cytology (n=19) (**Table 6B**). In this case the only one
483 patient identified HSIL by cytology but not predicted HSIL by HPV RNA-Seq (sample
484 IonXpress_020_3137) was found HSIL by the histological examination done 350 days later, which

485 opens the possibility that this sample might be positive if the patient would be tested again by HPV
486 RNA-Seq at a date closer to the histological examination.

487

488 In clinical use, after primary screening for high-risk HPV in the general population, a triage test with
489 high Sp and PPV is needed for the triage of women at risk of transforming infection before colposcopy.

490 In countries that have adopted HPV DNA as a screening test, cytological analysis can be used for the
491 triage of women at risk because cytology has better Sp and PPV than HPV DNA tests^{31,32}. In line with
492 that, the $PPV_{(cyto)}=81.8\%$ of HPV RNA-Seq outperformed HPV DNA and other RNA tests, whose PPV as
493 triage assays never exceed 50% in a population of women referred for colposcopy composed with a
494 similar 1:1 ratio of HSIL to LSIL¹⁰.

495

496 We thus sought to evaluate the added value of HPV RNA-Seq over cytology for the triage of women at
497 risk of developing cervical cancer. To do so, histology was used as the gold standard for the diagnosis
498 of cervical lesions. However, an inherent limitation of this work was that histology was not
499 concomitant with the sampling carried out for HPV RNA-Seq/cytology tests, which means that by the
500 time histology was performed (between 0 and 780 days after initial sampling), the lesion could have
501 evolved spontaneously in one direction (LSIL to HSIL) or another (HSIL to LSIL). To help clarify this point
502 we compared side to side the performances of HPV RNA-Seq vs histology to the performances of
503 cytology vs histology, considering different categories of samples (**Supplemental Table S4**).
504 Remarkably, whatever the category considered, the Sp of HPV RNA-Seq vs histology was always
505 greater than or equal to the Sp of cytology vs histology (+0.0 to +11.1), and the resulting PPV of HPV
506 RNA-Seq vs histology was always greater than the PPV of cytology vs histology (+2.4 to +7.4 in this
507 population reflecting others studies⁹) (**Supplemental Table S4**). Calculation of PPV as a function of HSIL
508 prevalence allowed anticipating a delta PPV between HPV RNA-Seq vs histology and cytology vs
509 histology. For example, in the case where the ratio of HSIL to LSIL would tend to 1:2 as seen
510 elsewhere¹⁰, the delta PPV could be up to +10.4 in favor of HPV RNA-Seq vs histology (range: +4.4 to
511 +10.4, (**Supplemental Figure 3** and **Supplemental Table S4**). This observation constitutes a solid

512 argument in favor of a potential added medical value of HPV RNA-Seq over cytology, although studies
513 on larger cohorts are now required. Another observation is that the Se of HPV RNA-Seq vs histology
514 was always higher on the subset of HPV-positive patients (+12.0 to +33.3, **Supplemental Table S4**),
515 similarly to the evaluation done with cytology taken as reference (**Table 6**). Lastly, the Sp of HPV RNA-
516 Seq vs histology increased on the subset of patients for whom histology was performed less than 3
517 months after sampling (+5.0 to +8.3, **Supplemental Table S4**) but decreased on the subset of patients
518 for whom histology was performed less than 6 months after sampling (-1.7 to -2.3, **Supplemental Table**
519 **S4**), which may indicate that some lesions have evolved in the meantime.

520

521 Although the minimum number of reads required for the assay was not evaluated, our observations
522 tend to support that 1 million reads or less per sample is enough for performing HPV genotyping, but
523 more would be needed for HPV transcripts detection. We do realize for example that the absence of
524 detectable transcripts for a given HPV was assimilated to the absence of HPV transcripts in the sample,
525 which may not be true if sequencing depth was insufficient. Generally speaking, the questions of the
526 format of the test and of the model of use are of importance in the perspective of deploying NGS-
527 based *in-vitro* diagnostic tests. AmpliSeq, former product by Thermo Fisher Scientific developed for
528 Ion Proton and PGM instruments, has been transferred in 2018 to Illumina and is now fully compatible
529 with Illumina sequencers. In a decentralized laboratory model, it becomes possible that 4-6 samples
530 could run on a benchtop iSeq100 sequencer for a cost per sample around 200 USD, with RNA
531 extraction, quality controls and data analysis included (salaries and equipment excluded). In a more
532 centralized view where all regional samples would converge to one laboratory, the use of production-
533 scale sequencers such as the HiSeq or NovaSeq instruments could allow multiplexing up to 381
534 samples per run, potentially reducing the cost per sample to around 10-20 USD and thus making NGS-
535 based assays competitive over PCR-based tests. Another point is that not all sequences of HPV RNA-
536 Seq contributed equally to the result, with some of them giving useless or redundant information,
537 suggesting that the format of the test can also evolve to keep only the most informative target
538 sequences, while potentially reducing the depth of sequencing required for analysis and the

539 associated costs. For example, a reduction in the number of human sequences (hg) used as internal
540 controls could be considered.

541

542 HPV RNA-Seq will be further developed and validated as a companion test in HPV DNA-positive
543 patients or when the result of cytology is uncertain, in order to allow focusing the colposcopies to the
544 most relevant patients. It has recently been shown that only one third of women recommended for
545 colposcopy after primary HPV testing (DNA) and cytology had actually HSIL⁹. By increasing the positive
546 predictive value in detecting HSIL, HPV RNA-Seq could significantly increase the medical benefit-cost
547 ratio of colposcopies. The case of Atypical Squamous Cells of Undetermined Significance (ASCUS)
548 would also constitute an important patient's category to demonstrate an added value of the assay.
549 Once the performances and the medical benefit have been evaluated on large cohorts, such broad
550 range genotype papillomavirus transcriptome assay could eventually replace first line cytology and
551 DNA-based tests, by providing in a single procedure both HPV detection and genotyping together with
552 a molecular marker of high-grade lesions. Other diagnostic applications in HPV-associated anogenital
553 or head and neck cancers can also be envisioned.

554

555 In conclusion, HPV RNA-Seq can provide a second line test in HPV-positive patients in order to reduce
556 unnecessary colposcopies and even be used as a two-in-one test combining HPV typing with triage
557 capabilities. HPV RNA-Seq is minimally-invasive and is convenient for sample conserved at room
558 temperature. The assay will now require further clinical validation in larger cohorts.

559

560

561 **Acknowledgments:** The authors want to thank the Clinical Core of the Center of Translational Science
562 (CRT-CC) of Institut Pasteur for the management of all legal and ethical aspects of the study,
563 PathoQuest (Paris, France) and the Center for Translational Science (CRT) / Cytometry and Biomarkers
564 Unit of Technology and Service (CB UTechS) at Institut Pasteur for providing access to the sequencers.

565

566 **DECLARATIONS**

567 **Availability of data and material:** The datasets supporting the conclusions of this article are included
568 within the article and its additional files. The AmpliSeq custom panel is registered under number
569 WG_WG00141. Raw sequencing data are available on the NCBI SRA database under BioProject
570 accession number PRJNA525642.

571 **Authors' contribution:** ME and PP designed the study. PP designed the AmpliSeq custom panel. JM,
572 AGP, AN, HM and TH collected the gynecological samples. MF, MCD, LA, HL and IH managed the
573 samples at the HPV National Reference Center. IH contributed to the clinical protocol. MCD and MF
574 provided SiHa cells. PP and DC performed the sequencing experiments and analyzed the data. AB did
575 the biostatistical analysis. PP, ME and AB wrote the manuscript. ME supervised the study. All authors
576 read and approved the final manuscript.

577

578 **REFERENCES**

- 579 1. Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the
580 anus, according to sex and HIV status: a systematic review and meta-analysis. *Lancet Infect Dis*,
581 2018, 18:198–206
- 582 2. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, Jiang B, Goodman MT,
583 Sibug-Saber M, Cozen W, Liu L, Lynch CF, Wentzensen N, Jordan RC, Altekruze S, Anderson WF,
584 Rosenberg PS, Gillison ML. Human papillomavirus and rising oropharyngeal cancer incidence in
585 the United States. *J Clin Oncol Off J Am Soc Clin Oncol*, 2011, 29:4294–301
- 586 3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J,
587 Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer
588 worldwide. *J Pathol*, 1999, 189:12–9

- 589 4. Schiffman M, Doorbar J, Wentzensen N, de Sanjosé S, Fakhry C, Monk BJ, Stanley MA, Franceschi
590 S. Carcinogenic human papillomavirus infection. *Nat Rev Dis Primer*, 2016, 2:16086
- 591 5. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved
592 issues. *Nat Rev Cancer*, 2007, 7:11–22
- 593 6. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-
594 cycle of human papillomaviruses. *Vaccine*, 2012, 30 Suppl 5:F55-70
- 595 7. Shulzhenko N, Lyng H, Sanson GF, Morgun A. Ménage à trois: an evolutionary interplay between
596 human papillomavirus, a tumor, and a woman. *Trends Microbiol*, 2014, 22:345–53
- 597 8. Tornesello ML, Buonaguro L, Giorgi-Rossi P, Buonaguro FM. Viral and cellular biomarkers in the
598 diagnosis of cervical intraepithelial neoplasia and cancer. *BioMed Res Int*, 2013, 2013:519619
- 599 9. Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee
600 M, Martin RE, Gentile L, Peacock S, Stuart GCE, Franco EL, Coldman AJ. Effect of Screening With
601 Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia
602 at 48 Months: The HPV FOCAL Randomized Clinical Trial. *JAMA*, 2018, 320:43–52
- 603 10. Cuzick J, Cadman L, Mesher D, Austin J, Ashdown-Barr L, Ho L, Terry G, Liddle S, Wright C, Lyons
604 D, Szarewski A. Comparing the performance of six human papillomavirus tests in a screening
605 population. *Br J Cancer*, 2013, 108:908–13
- 606 11. Virtanen E, Kalliala I, Dyba T, Nieminen P, Auvinen E. Performance of mRNA- and DNA-based
607 high-risk human papillomavirus assays in detection of high-grade cervical lesions. *Acta Obstet
608 Gynecol Scand*, 2017, 96:61–8
- 609 12. Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, Gondara L, Franco EL, Coldman AJ,
610 Ogilvie GS, Jang D, Chernesky M, Krajden M. Aptima HPV Assay versus Hybrid Capture® 2 HPV
611 test for primary cervical cancer screening in the HPV FOCAL trial. *J Clin Virol Off Publ Pan Am Soc
612 Clin Virol*, 2017, 87:23–9
- 613 13. Ge Y, Christensen P, Luna E, Armylagos D, Xu J, Schwartz MR, Mody DR. Aptima Human
614 Papillomavirus E6/E7 mRNA Test Results Strongly Associated With Risk for High-Grade Cervical
615 Lesions in Follow-Up Biopsies. *J Low Genit Tract Dis*, 2018, 22:195–200

- 616 14. de Thurah L, Bonde J, Lam JUH, Rebolj M. Concordant testing results between various human
617 papillomavirus assays in primary cervical cancer screening: systematic review. *Clin Microbiol*
618 *Infect Off Publ Eur Soc Clin Microbiol Infect Dis*, 2018, 24:29–36
- 619 15. Hawkes D, Brotherton JML, Saville M. Not all HPV nucleic acid tests are equal: only those
620 calibrated to detect high grade lesions matter for cervical screening. *Clin Microbiol Infect Off*
621 *Publ Eur Soc Clin Microbiol Infect Dis*, 2018, 24:436–7
- 622 16. de Thurah L, Bonde J, Lam JUH, Rebolj M. Not all HPV nucleic acid tests are equal: only those
623 calibrated to detect high grade lesions matter for cervical screening: Response to “Concordant
624 testing results between various human papillomavirus assays in primary cervical cancer
625 screening: systematic review” by de Thurah, Bonde, Uyen, Lam and Rebolj. Published 27 May,
626 2017. *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis*, 2018, 24:438–9
- 627 17. Heard I, Cuschieri K, Geraets DT, Quint W, Arbyn M. Clinical and analytical performance of the
628 PapilloCheck HPV-Screening assay using the VALGENT framework. *J Clin Virol Off Publ Pan Am*
629 *Soc Clin Virol*, 2016, 81:6–11
- 630 18. Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segondy M, Sahasrabudde VV, Gravitt PE,
631 Hsing AW, Burk RD. Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete
632 Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70. *PLOS ONE*, 2013, 8:e72565
- 633 19. Kearse M, Moir R, Wilson A, Stones-Havas S, Cheung M, Sturrock S, Buxton S, Cooper A,
634 Markowitz S, Duran C, Thierer T, Ashton B, Meintjes P, Drummond A. Geneious Basic: an
635 integrated and extendable desktop software platform for the organization and analysis of
636 sequence data. *Bioinforma Oxf Engl*, 2012, 28:1647–9
- 637 20. Zheng Z-M, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional
638 regulation. *Front Biosci J Virtual Libr*, 2006, 11:2286–302
- 639 21. Wang X, Meyers C, Wang H-K, Chow LT, Zheng Z-M. Construction of a full transcription map of
640 human papillomavirus type 18 during productive viral infection. *J Virol*, 2011, 85:8080–92

- 641 22. Wentzensen N, Ridder R, Klaes R, Vinokurova S, Schaefer U, Doeberitz M von K. Characterization
642 of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions.
643 *Oncogene*, 2002, 21:419–26
- 644 23. Tang K-W, Alaei-Mahabadi B, Samuelsson T, Lindh M, Larsson E. The landscape of viral
645 expression and host gene fusion and adaptation in human cancer. *Nat Commun*, 2013, 4:2513
- 646 24. Peter M, Rosty C, Couturier J, Radvanyi F, Teshima H, Sastre-Garau X. MYC activation associated
647 with the integration of HPV DNA at the MYC locus in genital tumors. *Oncogene*, 2006, 25:5985–
648 93
- 649 25. Lu X, Lin Q, Lin M, Duan P, Ye L, Chen J, Chen X, Zhang L, Xue X. Multiple-integrations of HPV16
650 genome and altered transcription of viral oncogenes and cellular genes are associated with the
651 development of cervical cancer. *PloS One*, 2014, 9:e97588
- 652 26. Kraus I, Driesch C, Vinokurova S, Hovig E, Schneider A, von Knebel Doeberitz M, Dürst M. The
653 majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences
654 of known or predicted genes. *Cancer Res*, 2008, 68:2514–22
- 655 27. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR.
656 STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*, 2013, 29:15–21
- 657 28. Friedman J, Hastie T, Tibshirani R. Regularization Paths for Generalized Linear Models via
658 Coordinate Descent. *J Stat Softw*, 2010, 33:1–22
- 659 29. Dalstein V, Merlin S, Bali C, Saunier M, Dachez R, Ronsin C. Analytical evaluation of the
660 PapilloCheck test, a new commercial DNA chip for detection and genotyping of human
661 papillomavirus. *J Virol Methods*, 2009, 156:77–83
- 662 30. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, J F Snijders P, Petry K-U, Krüger Kjaer S,
663 Munk C, Iftner T. Comparison of the performance of different HPV genotyping methods for
664 detecting genital HPV types. *J Med Virol*, 2008, 80:1264–74
- 665 31. Cuzick J, Szaewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry
666 G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P. Management of

667 women who test positive for high-risk types of human papillomavirus: the HART study. *Lancet*
668 *Lond Engl*, 2003, 362:1871–6

669 32. Schneider A, Hoyer H, Lotz B, Leistritz S, Kühne-Heid R, Nindl I, Müller B, Haerting J, Dürst M.
670 Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk
671 HPV, routine cytology or colposcopy. *Int J Cancer*, 2000, 89:529–34

672

673

674 FIGURES AND TABLES

675

676 **Figure 1:** Transcription maps of 16 HPV. **(A)** Alignment of 16 high-risk or putative high-risk HPV
677 reference sequences, showing splice donor and acceptor sites known previously for HPV16²⁰ and
678 HPV18²¹ (green marks) or predicted by sequence homology for other genotypes (pink marks). Protein
679 coding genes are indicated on top (green arrows). Putative high-risk HPV are indicated by a star (*).
680 **(B)** Genomic coordinates of splice donor (SD) and splice acceptor (SA) sites. Green: previously known
681 sites^{20,21}. Pink: predicted sites based on sequences alignment. pA early and pA late: polyA signal
682 (early and late sites). put. bkpt: putative breakpoint for HPV DNA genome integration into the host
683 genome. Putative high-risk HPV are indicated by a star (*).

684 **Figure 2:** Receiver Operating Characteristic (ROC) curve. HPV DNA (PapilloCheck) was used as a
685 reference to evaluate the performances of HPV RNA-Seq for the detection of at least one HPV
686 genotype in a sample. Data: 55 patients. AUC: Area Under Curve.

687 **Figure 3:** Comparison of the number of HPV genotypes identified by HPV RNA-Seq and HPV DNA.
688 Vertical bars represent the number of HPV genotypes identified by HPV RNA-Seq at threshold value
689 of 150 reads (red) vs HPV DNA (PapilloCheck, black). Putative high-risk HPV are indicated by a star (*).
690 Data: 55 patients.

691

692

Table 1: HPV RNA-Seq AmpliSeq custom panel contents.

	sp	unsp	gen	fus	hg	
HPV16	14	11	4	18	0	
HPV18	18	12	4	18	0	
HPV31	14	11	4	18	0	
HPV33	13	9	4	18	0	
HPV35	14	10	4	18	0	
HPV39	10	8	4	18	0	
HPV45	14	10	4	18	0	
HPV51	10	9	4	18	0	
HPV52	16	11	4	18	0	
HPV56	16	10	4	18	0	
HPV58	13	8	4	18	0	
HPV59	14	8	4	18	0	
HPV66	15	8	4	18	0	
HPV68*	10	9	4	18	0	
HPV73*	13	10	4	18	0	
HPV82*	11	9	4	18	0	
human	0	0	0	0	30	
TOTAL	215	153	64	288	30	750

693 The number of target amplicons is indicated for each category (sp, unsp, gen, fus, hg) and for each
694 viral and cellular origin. Putative high-risk HPV are indicated by a star (*).

695

696

Table 2: Performances of HPV RNA-Seq for HPV detection.

		HPV DNA			
		HPV+	HPV-	Se _(HPV-DNA)	97.3%
HPV RNA-Seq	HPV+	36	3	Sp _(HPV-DNA)	83.3%
	HPV -	1	15	PPV _(HPV-DNA)	92.3%
					NPV _(HPV-DNA)

697 Performances of HPV RNA-Seq at threshold value of 150 reads vs HPV DNA (PapilloCheck) for HPV
698 detection. Sensitivity (Se), Specificity (Sp), Positive Predictive Value (PPV) and Negative Predictive
699 Value (NPV) are given. HPV+ means that at least one HPV genotype is identified in a patient. Data: 55
700 patients.

701

702 **Table 3:** Comparison of HPV RNA-Seq and HPV DNA for the classification of samples.

	HPV RNA-Seq	HPV DNA
Mono-infected samples	26	27
Multi-infected samples	13	10
HPV-negative samples	16	18

703 Number of mono-infected, multi-infected and HPV-negative samples by HPV RNA-Seq at threshold
704 value of 150 reads, vs HPV DNA (PapilloCheck). Data: 55 patients.

705

706 **Table 4:** Coefficients of the (ridge) logistic regression.

junction	coefficient	name_transcript_category	name_transcript_contents
(Intercept)	0.468298365		
SD2_SA10	-0.693322203	late	L1
SD3_SA4	0.545728771	early	(E1) E4 E5
SD1_SA4	0.387642812	early	(E6) E2 E5
SD2_SA4	-0.262522618	early	(E7) E2 E5

SD1_SA2	0.146954179	early	E6 E7
SD2_SA5	0.12050536	early	(E7) E2 E5
SD1_SA6	0.107204358	early	(E6) E4 E5
SD5_SA10	0.096088118	late	L1
SD3_SA6	0.093052957	early	(E1) E4 E5
SD1_SA5	0.092877361	early	(E6) E2 E5
SD2_SA6	-0.088655106	early	(E7) E4 E5
SD1_SA1	0.07669912	early	E6 E7
SD1_SA3	0.069688722	early	E6 E7
SD2_SA8	0.061867993	early	(E7) E4 E5
SD3_SA5	0.051702326	early	(E1) E4 E5
SD2_SA9	-0.040972141	late	L1
SD5_SA9	-0.026083777	late	L1
SD3_SA8	0	early	(E1) E4 E5

707 The first and fourth columns give the id of the splice junction captured by the amplicon, the second
708 column gives the coefficient assigned by the logistic regression and the third column indicates
709 whether the splice junction comes from a “late” or “early” transcript.

710

711 **Table 5:** Classification results of the (ridge) logistic regression.

sample	prediction_score	prediction_class	prediction_class	prediction_accuracy
lonXpress_039_115	0.115	-1	LSIL	TRUE
lonXpress_033_730	0.204	-1	LSIL	TRUE
lonXpress_038_114	0.259	-1	LSIL	TRUE
1492	0.425	-1	LSIL	TRUE
lonXpress_019_2613	0.562	1	LSIL	FALSE
lonXpress_027_598	0.653	1	HSIL	TRUE
729	0.716	1	HSIL	TRUE
567	0.718	1	HSIL	TRUE
lonXpress_018_2439	0.902	1	HSIL	TRUE

610	0.904	1	HSIL	TRUE
1066	0.911	1	HSIL	TRUE
lonXpress_034_758	0.919	1	HSIL	TRUE
1122	0.934	1	HSIL	TRUE
25	0.944	1	HSIL	TRUE
lonXpress_037_1267	0.947	1	HSIL	TRUE
lonXpress_024_26	0.965	1	HSIL	TRUE
lonXpress_025_538	0.97	1	HSIL	TRUE
752	0.976	1	HSIL	TRUE
lonXpress_021_443	0.984	1	HSIL	TRUE
2612	0.993	1	HSIL	TRUE

712 The first column gives the sample id, the second column gives the probability estimate that the
713 sample is HSIL, the third and fourth columns give the corresponding prediction, the fifth column
714 contains TRUE if the prediction is consistent with the grade evaluated by cytology.

715

716 **Table 6:** Performances of HPV RNA-Seq for the prediction of high-grade cytology.

A	Cytology			
		HSIL	LSIL	Se_(cyto) 66.7%
	HPV RNA-Seq	HSIL	18 4	Sp_(cyto) 85.7%
		Not HSIL	9 24	PPV_(cyto) 81.8%
			NPV_(cyto) 72.7%	

B	Cytology			
		HSIL	LSIL	Se_(cyto/HR+) 94.7%
	HPV RNA-Seq	HSIL	18 4	Sp_(cyto/HR+) 80.0%
	HR+	Not HSIL	1 16	PPV_(cyto/HR+) 81.8%
			NPV_(cyto/HR+) 94.1%	

717 Performances of HPV RNA-Seq vs cytology for HSIL detection (A) for the 55 patients and (B) for the
 718 subset of 39 patients having at least one HPV identified by HPV RNA-Seq. Sensitivity (Se), Specificity
 719 (Sp), Positive Predictive Value (PPV) and Negative Predictive Value (NPV) are given. “Not HSIL” means
 720 that either no HPV was detected in the sample by HPV RNA-Seq or that none of the HPV genotypes
 721 detected were given HSIL prediction.

722

723 **Table 7:** HPV detection and genotyping and HSIL prediction for the 55 clinical samples.

Sample name	HPV DNA	HPV RNA-Seq					Cytology	Histology	Time (days) cyto-histo
		Genotyping	Marker of HSIL			Prediction			
		Per patient	Per HPV		Per patient				
Detection	Not enough coverage on splice junctions	Not HSIL	HSIL						
D-15-0041_1066_BC13	16	16			16	HSIL	HSIL	HSIL	55
D-15-0041_1122_BC14	16	16			16	HSIL	HSIL	HSIL	130
D-15-0041_1124_BC5	16,39	16,39	39	16		Not HSIL	LSIL	HSIL	[70-434]
D-15-0041_1490_BC6	16,39	16,35,39		39	16,35	HSIL	LSIL	HSIL	67
D-15-0041_1492_BC7	16	16		16		Not HSIL	LSIL	LSIL	81
D-15-0041_151_BC15	16,(53)	16			16	HSIL	LSIL	HSIL	130
D-15-0041_152_BC16	16,(42)	16,52,82	16,52,82			Not HSIL	LSIL	LSIL	41
D-15-0041_2209_BC11	16,(42),52	16,39,52	39	16,52		Not HSIL	LSIL	HSIL	n.d.
D-15-0041_250_BC12	16,39,(42)	16,39		16,39		Not HSIL	LSIL	LSIL	55
D-15-0041_25_BC4	16	16			16	HSIL	HSIL	HSIL	75
D-15-0041_2612_BC8	16	16			16	HSIL	HSIL	n.d.	n.d.
D-15-0041_567_BC9	16	16			16	HSIL	HSIL	HSIL	n.d.
D-15-0041_610_BC2	16	16			16	HSIL	HSIL	HSIL	113
D-15-0041_729_BC3	16	16			16	HSIL	HSIL	HSIL	59
D-15-0041_752_BC10	16	16			16	HSIL	HSIL	HSIL	444
IonXpress_017_2437	(43),51	51		51		Not HSIL	LSIL	LSIL	195
IonXpress_017_251	neg	neg				Not HSIL	HSIL	LSIL	85
IonXpress_018_2439	58	58			58	HSIL	HSIL	LSIL	164
IonXpress_018_440	neg	neg				Not HSIL	LSIL	LSIL	38
IonXpress_019_2613	16	16			16	HSIL	LSIL	HSIL	[416-780]
IonXpress_020_3137	(53)	56	56			Not HSIL	HSIL	HSIL	350
IonXpress_021_10	56,(44/55)	56		56		Not HSIL	LSIL	n.d.	130
IonXpress_021_443	58	33,58	33		58	HSIL	HSIL	LSIL	99
IonXpress_022_23	neg	neg				Not HSIL	HSIL	HSIL	n.d.
IonXpress_022_444	16,33	16,33		33	16	HSIL	HSIL	HSIL	69
IonXpress_023_24	(6),(11),(53)	neg				Not HSIL	HSIL	HSIL	[0-13]

lonXpress_023_536	neg	neg				Not HSIL	LSIL	LSIL	101
lonXpress_024_26	45	45			45	HSIL	HSIL	HSIL	106
lonXpress_024_537	neg	neg				Not HSIL	LSIL	LSIL	71
lonXpress_025_457	neg	neg				Not HSIL	LSIL	LSIL	278
lonXpress_025_538	35	31,35	31		35	HSIL	HSIL	HSIL	191
lonXpress_026_539	neg	neg				Not HSIL	LSIL	n.d.	n.d.
lonXpress_026_565	16	neg				Not HSIL	HSIL	HSIL	65
lonXpress_027_598	31	31			31	HSIL	HSIL	HSIL	52
lonXpress_028_609	35,52	52			52	HSIL	LSIL	HSIL	83
lonXpress_029_611	neg	neg				Not HSIL	HSIL	n.d.	n.d.
lonXpress_030_612	neg	neg				Not HSIL	LSIL	LSIL	113
lonXpress_031_613	35,39,(44/55)	35,39		35,39		Not HSIL	LSIL	LSIL	83
lonXpress_032_728	neg	neg				Not HSIL	HSIL	HSIL	59
lonXpress_033_730	31	31		31		Not HSIL	LSIL	HSIL	[211-575]
lonXpress_034_758	58	58			58	HSIL	HSIL	HSIL	43
lonXpress_035_1150	16,39,52	16,39,52		52	16,39	HSIL	HSIL	HSIL	125
lonXpress_036_1151	(11),31	31			31	HSIL	HSIL	HSIL	125
lonXpress_036_98	(42)	neg				Not HSIL	LSIL	n.d.	20
lonXpress_037_100	neg	neg				Not HSIL	LSIL	LSIL	57
lonXpress_037_1267	45	45			45	HSIL	HSIL	LSIL	71
lonXpress_038_114	31	31		31		Not HSIL	LSIL	HSIL	154
lonXpress_038_1597	neg	neg				Not HSIL	HSIL	HSIL	85
lonXpress_039_115	56	56		56		Not HSIL	LSIL	LSIL	34
lonXpress_039_1598	neg	neg				Not HSIL	HSIL	LSIL	115
lonXpress_041_1650	66,(70)	56,66	56,66			Not HSIL	LSIL	LSIL	115
lonXpress_043_1871	51,58,68,73	33,51,58,68	33	51,58,68		Not HSIL	LSIL	LSIL	101
lonXpress_044_2064	39,51	45	45			Not HSIL	LSIL	HSIL	129
lonXpress_045_2065	neg	52,58	52,58			Not HSIL	LSIL	LSIL	160
lonXpress_046_2066	(6)	66	66			Not HSIL	LSIL	HSIL	99

724 HPV genotypes included in the scope of the HPV DNA test (PapilloCheck) but not in HPV RNA-Seq are
725 indicated into brackets. For each genotype identified by HPV RNA-Seq, a classification is given: either
726 “Not enough coverage on splice junctions” (no prediction was possible for the genotype), “Not HSIL”
727 or “HSIL”. When at least one HPV was given high-grade signature, the patient’s prediction was set as
728 “HSIL”. Conversely, a final “Not HSIL” means that either no HPV was detected in the sample, or that
729 none of the HPV genotypes detected were given HSIL prediction.

730

731

732 **Supplemental Figure 1:** Evaluation of transport medium for RNA conservation: detection of cellular and
733 viral transcripts by RT-qPCR at D0, D2, D7, D14 and D21. (A) Cellular transcripts GAPDH and G6PD

734 (average values), (B) Viral transcripts E6 & E7 (average values). The relative abundance (y-axis, log
735 scale) is calculated in comparison to the higher expression value of the dataset, set to 1. Time scale (x-
736 axis, hours): 2 hours (D0), 48 hours (D2), 168 hours (D7), 336 hours (D14), 504 hours (D21). (JPEG
737 2233 Ko)

738 **Supplemental Figure 2:** Evaluation of transport medium for RNA conservation: RNA integrity at D0, D2,
739 D7, D14 and D21. Bioanalyzer gel-like visualization of RNA profiles, showing 18S and 28S rRNA
740 populations (two distinct bands) as a marker of RNA integrity. (JPEG 788 Ko)

741 **Supplemental Figure 3:** Positive Predictive Value (PPV) of HPV RNA-Seq vs histology (in blue) and of
742 cytology vs histology (in red) function of the prevalence of HSIL in the population (P HSIL). Calculations
743 are provided in the Supplemental Table S4. (JPEG 2780 Ko)